Dančík Vlado, Carrel Hyman, Bodycombe Nicole E, Seiler Kathleen Petri, Fomina-Yadlin Dina, Kubicek Stefan T, Hartwell Kimberly, Shamji Alykhan F, Wagner Bridget K, Clemons Paul A
Center for the Science of Therapeutics, Broad Institute of Harvard and MIT, Cambridge, MA, USA Mathematical Institute of the Slovak Academy of Sciences, Košice, Slovakia (on leave).
Center for the Science of Therapeutics, Broad Institute of Harvard and MIT, Cambridge, MA, USA.
J Biomol Screen. 2014 Jun;19(5):771-81. doi: 10.1177/1087057113520226. Epub 2014 Jan 24.
High-throughput screening allows rapid identification of new candidate compounds for biological probe or drug development. Here, we describe a principled method to generate "assay performance profiles" for individual compounds that can serve as a basis for similarity searches and cluster analyses. Our method overcomes three challenges associated with generating robust assay performance profiles: (1) we transform data, allowing us to build profiles from assays having diverse dynamic ranges and variability; (2) we apply appropriate mathematical principles to handle missing data; and (3) we mitigate the fact that loss-of-signal assay measurements may not distinguish between multiple mechanisms that can lead to certain phenotypes (e.g., cell death). Our method connected compounds with similar mechanisms of action, enabling prediction of new targets and mechanisms both for known bioactives and for compounds emerging from new screens. Furthermore, we used Bayesian modeling of promiscuous compounds to distinguish between broadly bioactive and narrowly bioactive compound communities. Several examples illustrate the utility of our method to support mechanism-of-action studies in probe development and target identification projects.
高通量筛选能够快速鉴定出用于生物探针或药物开发的新候选化合物。在此,我们描述了一种有原则的方法,可为单个化合物生成“测定性能概况”,作为相似性搜索和聚类分析的基础。我们的方法克服了与生成稳健的测定性能概况相关的三个挑战:(1)我们对数据进行转换,使我们能够从具有不同动态范围和变异性的测定中构建概况;(2)我们应用适当的数学原理来处理缺失数据;(3)我们减轻了信号损失测定测量可能无法区分多种可导致某些表型(如细胞死亡)的机制这一事实。我们的方法将具有相似作用机制的化合物联系起来,能够预测已知生物活性物质以及新筛选出的化合物的新靶点和机制。此外,我们使用混杂化合物的贝叶斯模型来区分广泛生物活性和狭窄生物活性的化合物群落。几个例子说明了我们的方法在支持探针开发和靶点鉴定项目中的作用机制研究方面的实用性。